CNR2 and postmenopausal osteoporosis: For instance, it has been demonstrated that a missense variant (Gln63Arg) of CNR2, which was strongly associated with BMD in a population of postmenopausal osteoporosis patients, affects cannabinoid receptor type 2 (CB2) expression and activity [34].